Category: Markets
Published: 2026-07-16T11:58:09.000Z
Oppenheimer has increased its price target for UroGen Pharma (NASDAQ:URGN) to $50 from $40, maintaining an Outperform rating, based on increased sales projections for their Jelmyto product. The firm's updated estimates for Jelmyto sales in 2026-28 are $210 million, $448 million, and $648 million, respectively, higher than previous forecasts and consensus estimates. This positive outlook comes as UroGen Pharma shares have seen significant growth, rising 110% since April 1 and 178% over the past year, while also advancing with a new patent for bladder cancer treatment and FDA clearance for a new oncolytic virus candidate.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.